Overview

Long-term Study of CS-3150 as Monotherapy or in Combination With Other Antihypertensive Drug in Japanese Patients With Essential Hypertension

Status:
Completed

Trial end date:
2017-07-08

Target enrollment:

Participant gender:

Summary

To examine antihypertensive effect, pharmacodynamics, and safety of long-term administration of CS-3150 as monotherapy and in combination with calcium channel blocker or renin-angiotensin system inhibitor in patients with essential hypertension.

Phase:

Phase 3

Details

Lead Sponsor:

Daiichi Sankyo Co., Ltd.

Treatments:

Antihypertensive Agents
Mineralocorticoid Receptor Antagonists